Biogen (BIIB) PT Lowered to $340 at Goldman Sachs
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $199.71 --0%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter lowered the price target on Biogen (NASDAQ: BIIB) to $340.00 (from $393.00) while maintaining a Buy rating.
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Skyworks Solutions (SWKS) PT Raised to $80 at RBC Capital
- Hyundai Motor (005380:KS) (HYMLF) PT Raised to MYR670,000 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
